Company / Cash & Equivalents
Aquestive Therapeutics, Inc. Cash & Equivalents History
FY2018-FY2020 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Cash & Equivalents
$31.8M
FY2020
5-year range
-
FY2018-FY2020
Trend
-35.5%
vs FY2019
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Declined from $61M to $32M over the past 2 years.
Based on SEC 10-K filings.
$32M in FY2020.
Declined from $61M to $32M over the past 2 years.
Cash & Equivalents over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Key checks
Key Insights
- In FY2020, cash & equivalents decreased 35.5% year-over-year.
Company context
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Altman Z-Score -3.08 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Cash & EquivalentsValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | - | - |
| FY2024 | - | - |
| FY2023 | - | - |
| FY2022 | - | - |
| FY2021 | - | - |
| FY2020 | $31.8M | -35.5% |
| FY2019 | $49.3M | -18.6% |
| FY2018 | $60.6M | - |
As of FY2020 · SEC 10-K · Updated Jun 24, 2026